{"id":"bispecific-antibody","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Nausea"},{"rate":"15%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL2109418","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bispecific antibodies are designed to bind to two different antigens, in this case CD16A and CD19, to enhance the immune response against cancer cells.","oneSentence":"Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:24:30.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT07181941","phase":"PHASE1, PHASE2","title":"Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-03-24","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT06015880","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-20","conditions":"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT06337318","phase":"PHASE3","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-23","conditions":"Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features","enrollment":600},{"nctId":"NCT03739814","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-08","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":84},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT05675449","phase":"PHASE1","title":"A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-12-14","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":53},{"nctId":"NCT06215118","phase":"PHASE1","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-20","conditions":"Multiple Myeloma","enrollment":87},{"nctId":"NCT07491900","phase":"PHASE1","title":"A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)","status":"RECRUITING","sponsor":"Hinge Bio","startDate":"2026-03-23","conditions":"Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)","enrollment":30},{"nctId":"NCT07462377","phase":"PHASE1","title":"A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC","status":"RECRUITING","sponsor":"EpiBiologics","startDate":"2026-04","conditions":"Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation","enrollment":110},{"nctId":"NCT06925724","phase":"PHASE2","title":"A Study of Ivonescimab in People With Endometrial and Cervical Cancers","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-04","conditions":"Endometrial Cancer, Cervical Cancer","enrollment":50},{"nctId":"NCT06975787","phase":"PHASE1","title":"Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-12-22","conditions":"Lupus Nephritis (LN)","enrollment":90},{"nctId":"NCT06932562","phase":"PHASE3","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","status":"RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2025-12-23","conditions":"Multiple Myeloma","enrollment":1000},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT04995523","phase":"PHASE1, PHASE2","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-14","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":212},{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT07151690","phase":"PHASE2","title":"BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-04","conditions":"Systemic Light Chain Amyloidosis","enrollment":21},{"nctId":"NCT06149286","phase":"PHASE3","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-28","conditions":"Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)","enrollment":470},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT05123482","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer","enrollment":460},{"nctId":"NCT06585891","phase":"PHASE1","title":"Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-10-07","conditions":"HIV Infection","enrollment":24},{"nctId":"NCT07218003","phase":"PHASE1","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","status":"ENROLLING_BY_INVITATION","sponsor":"Rondo Therapeutics","startDate":"2025-11-17","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer","enrollment":149},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":"Large B-cell Lymphoma","enrollment":420},{"nctId":"NCT06647069","phase":"PHASE1","title":"A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-27","conditions":"Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA)","enrollment":62},{"nctId":"NCT05681884","phase":"PHASE2","title":"Safety and Efficacy of Faricimab in Patients With NPDR","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2023-05-16","conditions":"Non-Proliferative Diabetic Retinopathy","enrollment":179},{"nctId":"NCT06057402","phase":"PHASE4","title":"Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-10-03","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT07101328","phase":"PHASE1","title":"A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 )","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-06","conditions":"Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":215},{"nctId":"NCT07258511","phase":"PHASE3","title":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2026-02-04","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT05411133","phase":"PHASE1","title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","status":"COMPLETED","sponsor":"Arbele Pty Ltd","startDate":"2022-05-30","conditions":"Gastrointestinal Cancer, Cholangiocarcinoma, Liver Cancer","enrollment":33},{"nctId":"NCT07222761","phase":"PHASE3","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-01-02","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":915},{"nctId":"NCT06892548","phase":"PHASE1, PHASE2","title":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-05-02","conditions":"Advanced Lung Cancer","enrollment":594},{"nctId":"NCT05828511","phase":"PHASE1, PHASE2","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-19","conditions":"Multiple Myeloma","enrollment":149},{"nctId":"NCT05689853","phase":"PHASE1, PHASE2","title":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-04-14","conditions":"Solid Tumor, Adult","enrollment":87},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":"Untreated Follicular Lymphoma","enrollment":1018},{"nctId":"NCT04140500","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-11-11","conditions":"Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer","enrollment":170},{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT05702229","phase":"PHASE2","title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-01-16","conditions":"Gastric Cancer","enrollment":163},{"nctId":"NCT04889716","phase":"PHASE2","title":"CAR-T Followed by Bispecific Antibodies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-05","conditions":"Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT04594642","phase":"PHASE1","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-03-02","conditions":"B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":317},{"nctId":"NCT04634552","phase":"PHASE2","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hematological Malignancies","enrollment":510},{"nctId":"NCT03070392","phase":"PHASE2","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","status":"COMPLETED","sponsor":"Immunocore Ltd","startDate":"2017-10-16","conditions":"Uveal Melanoma","enrollment":378},{"nctId":"NCT06276491","phase":"PHASE1","title":"Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Xencor, Inc.","startDate":"2024-04-04","conditions":"Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor","enrollment":282},{"nctId":"NCT04077463","phase":"PHASE1","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-09-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":701},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT07221253","phase":"PHASE3","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-04","conditions":"Biliary Tract Cancer","enrollment":1100},{"nctId":"NCT07115043","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-29","conditions":"Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)","enrollment":60},{"nctId":"NCT06712316","phase":"PHASE2, PHASE3","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-01-07","conditions":"Non-small Cell Lung Cancer","enrollment":1260},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT06840834","phase":"PHASE2","title":"Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-06-30","conditions":"Pleural Mesotheliomas","enrollment":38},{"nctId":"NCT05663866","phase":"PHASE2","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-05-18","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":68},{"nctId":"NCT07393282","phase":"PHASE3","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-25","conditions":"High Risk Smoldering Multiple Myeloma (HR-SMM)","enrollment":270},{"nctId":"NCT07474961","phase":"PHASE4","title":"BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.","status":"NOT_YET_RECRUITING","sponsor":"Anne Louise Tølbøll Sørensen","startDate":"2027-03","conditions":"Waldenstrom Macroglobulinaemia, Multiple Myeloma","enrollment":400},{"nctId":"NCT07473726","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-05-17","conditions":"Advanced/Metastatic Solid Tumors","enrollment":72},{"nctId":"NCT05783596","phase":"PHASE2","title":"Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-07-18","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":47},{"nctId":"NCT06150157","phase":"PHASE1","title":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-20","conditions":"Neoplasms","enrollment":220},{"nctId":"NCT04703686","phase":"PHASE2","title":"Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-30","conditions":"Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma","enrollment":67},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":32},{"nctId":"NCT06510361","phase":"PHASE2","title":"Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-11-20","conditions":"Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin","enrollment":35},{"nctId":"NCT07218510","phase":"PHASE2","title":"Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-07","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":33},{"nctId":"NCT06784726","phase":"PHASE2","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-09-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT06841055","phase":"PHASE2","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-03-03","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07270978","phase":"PHASE1","title":"Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2026-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":23},{"nctId":"NCT04108195","phase":"PHASE1","title":"A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-21","conditions":"Multiple Myeloma","enrollment":290},{"nctId":"NCT06510491","phase":"PHASE2","title":"Epcoritamab in Previously Treated WM","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2024-12-06","conditions":"Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder","enrollment":20},{"nctId":"NCT06442475","phase":"PHASE2","title":"Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-08-29","conditions":"Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma","enrollment":20},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06178614","phase":"PHASE1","title":"A Study of JNJ-87890387 for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-14","conditions":"Neoplasms, Advanced Solid Tumors","enrollment":200},{"nctId":"NCT07128641","phase":"PHASE2","title":"Odronextamab in Low Tumor Volume Advanced FL","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2025-09-08","conditions":"Follicular Lymphoma, Lymphoma","enrollment":35},{"nctId":"NCT06479239","phase":"PHASE1, PHASE2","title":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-11-06","conditions":"Pancreas Cancer, Pancreatic Cancer","enrollment":23},{"nctId":"NCT07133997","phase":"PHASE1","title":"Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-06-01","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":26},{"nctId":"NCT04606381","phase":"PHASE1","title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-10","conditions":"Neoplasms","enrollment":158},{"nctId":"NCT04557098","phase":"PHASE2","title":"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-17","conditions":"Hematological Malignancies","enrollment":194},{"nctId":"NCT04696809","phase":"PHASE1, PHASE2","title":"A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-02-22","conditions":"Hematologic Malignancies","enrollment":40},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT07297212","phase":"PHASE2","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-01-15","conditions":"Recurrent Glioblastoma","enrollment":75},{"nctId":"NCT03145181","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-05-16","conditions":"Hematological Malignancies","enrollment":302},{"nctId":"NCT03399799","phase":"PHASE1","title":"Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-16","conditions":"Hematological Malignancies","enrollment":279},{"nctId":"NCT05338775","phase":"PHASE1","title":"A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-05-25","conditions":"Relapsed/ Refractory Multiple Myeloma","enrollment":74},{"nctId":"NCT07070232","phase":"PHASE1, PHASE2","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-08-12","conditions":"Advanced Solid Tumor","enrollment":980},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":"Follicular Lymphoma (FL)","enrollment":822},{"nctId":"NCT06976476","phase":"PHASE2","title":"Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-08","conditions":"Multiple Myeloma, Hypogammaglobulinemia, Hypogammaglobulinemia, Acquired","enrollment":100},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT07000149","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma","enrollment":1116},{"nctId":"NCT07348055","phase":"PHASE1, PHASE2","title":"A Study of GR1803 in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2026-02-02","conditions":"Systemic Lupus Erthematosus, Auto Immune Disease","enrollment":44},{"nctId":"NCT07460362","phase":"PHASE2","title":"Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-08-11","conditions":"MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)","enrollment":43},{"nctId":"NCT06890494","phase":"EARLY_PHASE1","title":"Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-01-18","conditions":"Leukemia","enrollment":3},{"nctId":"NCT07340476","phase":"PHASE1","title":"A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2025-12-11","conditions":"Healthy Male Subjects","enrollment":108},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT05229497","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-05-04","conditions":"Advanced Malignant Tumors","enrollment":154},{"nctId":"NCT06951646","phase":"PHASE2","title":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-10","conditions":"Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)","enrollment":70},{"nctId":"NCT07455734","phase":"PHASE1, PHASE2","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"BioNTech SE","startDate":"2026-03","conditions":"Advanced Solid Tumor Cancer","enrollment":533}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Bispecific antibody","genericName":"Bispecific antibody","companyName":"Sung-Soo Park","companyId":"sung-soo-park","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis Used for Treatment of relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}